灯蓝app破解版

灯蓝app破解版

Male Apellis employee holding a horse saddle

Luis
Supply Chain at Apellis

灯蓝app破解版

Learn More
Folded page of a newspaper

灯蓝app破解版

灯蓝app破解版

Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results

灯蓝app破解版

Apellis Completes Enrollment in Two Phase 3 Studies of the Targeted C3 Therapy, Pegcetacoplan, in Patients with Geographic Atrophy (GA)

w加速器官网

Apellis Completes Enrollment in Phase 3 Study of Pegcetacoplan in Treatment-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Newsroom
w加速器安卓

@ApellisPharma

A man with a baby in a baby carrier

灯蓝app破解版

FOR PATIENTS
Erlenmeyer flask, which represents the pre-clinical and clinical studies sponsored by Apellis Pharmaceuticals

灯蓝app破解版

for paroxysmal nocturnal hemoglobinuria, geographic atrophy,
C3 glomerulopathy, and cold agglutinin disease.

PIPELINE
3 arrows of different lengths, which represents the development status of pre-clinical and clinical studies for C3 complement targeted therapies

灯蓝app破解版

are targeted C3 therapies. These include potential medicines for a broad range of serious diseases driven by uncontrolled or excessive activation of the complement system.

CLINICAL TRIALS

灯蓝app破解版

so that Alexander, who is living with C3 glomerulopathy, can take his pug for a hike

We challenge conventional thinking and always question if there's a better way.

Join Us
w加速器app

Patricia
Quality Assurance at Apellis

蓝灯vn  快橙vp n官网  永远连得上  快连vpe下载  快连vp n官  旋风 加速  sdp加速器  电脑vp加速器